Ditchcarbon
  • Contact
  1. Organizations
  2. Akorn
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 19 days ago

Akorn Sustainability Profile

Company website

Akorn, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and operates extensively across North America. Founded in 1971, the company has established itself as a leader in the development, manufacturing, and marketing of specialty pharmaceuticals, particularly in the areas of ophthalmology, anaesthesia, and injectables. With a diverse portfolio of products, Akorn is recognised for its commitment to quality and innovation, offering unique formulations that cater to specific patient needs. The company has achieved significant milestones, including the expansion of its manufacturing capabilities and a robust pipeline of generic and branded medications. Akorn's strategic focus on niche markets has solidified its position as a trusted provider in the competitive pharmaceutical landscape.

DitchCarbon Score

How does Akorn's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

29

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Akorn's score of 29 is lower than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.

50%

Let us know if this data was useful to you

Akorn's reported carbon emissions

As of the latest available data, Akorn has not reported any specific carbon emissions figures. However, the company has established significant climate commitments aimed at achieving net-zero carbon emissions. Akorn's initiatives include a near-term target for new buildings to be net-zero carbon emitters by 2030 and existing buildings by 2050, focusing on Scope 1 emissions. This commitment reflects a proactive approach to sustainability in the property sector, particularly in markets such as the United Kingdom. While no specific reduction percentages or absolute emissions data are available, Akorn's long-term vision aligns with global trends towards stringent climate policies and sustainable building practices. The absence of reported emissions data suggests that Akorn is in the early stages of its climate strategy, with a clear focus on future compliance and environmental responsibility.

How Carbon Intensive is Akorn's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Akorn's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Akorn's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Akorn is in US, which has a low grid carbon intensity relative to other regions.

Akorn's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Akorn has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Akorn's Emissions with Industry Peers

Zydus Lifesciences

IN
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Accord Healthcare Limited

GB
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Zydus Pharmaceuticals

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

ADVANZ PHARMA Corp. Limited

GB
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251104.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy